news
Verona Pharma announces positive headline data from RPL554 trial
15 March 2016 | By Victoria White
The study met its primary objective, with nebulised RPL554 demonstrating a dose-dependent bronchodilator response in asthma patients...
List view / Grid view
COPD
news
Do asthma and COPD exist? Experts call for a new approach to patient management
1 February 2016 | By Victoria White
Defining a patient’s symptoms using the historical diagnostic labels of asthma and COPD is an outdated approach, according to experts...
news
AstraZeneca to acquire Takeda’s respiratory business
17 December 2015 | By Victoria White
AstraZeneca is to acquire the core respiratory business of Takeda for $575 million, adding Daxas to its portfolio...
news
Global COPD treatment market to hit $11.2 billion by 2021, says GBI Research
3 December 2015 | By Victoria White
GBI Research says the market will rise at a steady CAGR of 2.9% from $9.2 billion in 2014 to $11.2 billion in 2021...
news
Novartis announces new trial results for Ultibro Breezhaler in COPD
17 November 2015 | By Victoria White
Once-daily Ultibro Breezhaler met its primary endpoint (non-inferiority) and also demonstrated superiority to twice-daily Seretide...
news
Verona Pharma starts RPL554 Phase IIa combination study
14 October 2015 | By Victoria White
Verona Pharma has announced that the first patients have been dosed in a Phase IIa combination study to evaluate the addition of RPL554 to standard reliever medications for COPD...
news
Phase 3 programme for revefenacin in COPD starts
14 September 2015 | By Victoria White
The Phase 3 programme includes two replicate three-month efficacy studies and a single 12-month safety study...
news
Results from the SUMMIT COPD CV survival study announced
9 September 2015 | By Victoria White
For the primary endpoint of the study, the risk of dying on Relvar/Breo Ellipta 100/25mcg was 12.2% lower than on placebo over the study period, which was not statistically significant...
news
Spiolto Respimat provides meaningful quality of life improvements in COPD
17 August 2015 | By Victoria White
New data show Spiolto Respimat provides consistent, clinically meaningful improvements in quality of life versus placebo in patients COPD...
news
COPD maintenance treatment, Spiolto Respimat, approved in first European countries
2 July 2015 | By Victoria White
Boehringer Ingelheim today announced regulatory authority approvals for Spiolto Respimat (tiotropium/olodaterol) in a number of European countries...
news
FDA approves Stiolto Respimat Inhalation Spray as once-daily maintenance treatment of COPD
28 May 2015 | By Victoria White
The US Food and Drug Administration has approved Boehringer Ingelheim’s once-daily Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray...
news
Novartis announces two positive US phase III programmes in COPD for QVA149 and NVA237
22 May 2015 | By Victoria White
Novartis has announced positive results from two pivotal Phase III clinical trial programmes for QVA149 and NVA237 in patients with moderate-to-severe COPD...
news
New data analyses show benefit of tiotropium / olodaterol Respimat from the start of COPD maintenance therapy
21 May 2015 | By Victoria White
New data shows tiotropium/olodaterol Respimat provides lung function benefit to patients with COPD from the start of maintenance therapy...
news
New standard of care could prevent future cases of occupational COPD and 4000 deaths a year
20 May 2015 | By Victoria White
The Society of Occupational Medicine has published new standards of care that, if followed, could prevent future cases of COPD...
news
New research in the international medical journal CHEST showed patients had reduced hospital stays, medical costs and returns to the hospital
People aged 65 and older, who were being treated for chronic obstructive pulmonary disease (COPD) in the hospital and received nutrition treatment (oral nutrition supplements) had reduced lengths of stay, hospital costs and chances of returning to the hospital within 30-days, according to a study published in CHEST...
